Piper Jaffray analyst David Amsellem raised his price target for Pacira Pharmaceuticals to $51 after increasing his estimates for Exparel. Recent monthly sales data make it clear that the nerve block label expansion is having a real impact, Amsellem tells investors in a research note. The analyst believes Pacira is well positioned to deliver Exparel sales growth that is “solidly in the double digits for the foreseeable future.” He reiterates an Overweight rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.